diffuse large B-cell lymphoma activated B-cell type | ClinicalTrials HQ

View definition

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma	B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, T-cell/histiocyte rich large B cell lymphoma, diffuse large B-cell lymphoma, diffuse large B-cell lymphoma activated B-cell type, diffuse large B-cell lymphoma germinal center B-cell type, immune system disorder, immunoproliferative disorder, intravascular large B-cell lymphoma, lymphatic system disorder, lymphoma, lymphoplasmacytic lymphoma, lymphoproliferative syndrome, neoplasm, primary cutaneous diffuse large B-cell lymphoma, Leg type	Active, not recruiting	Phase 2 / Phase 3	2026-10-01		NCT04799275
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas	ALK-positive large B-cell lymphoma, B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Tumor Virus Infections, diffuse large B-cell lymphoma, diffuse large B-cell lymphoma activated B-cell type, diffuse large B-cell lymphoma germinal center B-cell type, diffuse large B-cell lymphoma of the central nervous system, immune system disorder, immunoproliferative disorder, intravascular large B-cell lymphoma, lymphatic system disorder, lymphoma, lymphomatoid granulomatosis, lymphoproliferative syndrome, neoplasm, plasmablastic lymphoma, precancerous condition, primary effusion lymphoma, viral infectious disease	Active, not recruiting	Phase 2	2026-05-12		NCT03038672